Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash & Equivalents: 2016-2019

Historic Cash & Equivalents for Monopar Therapeutics (MNPR) over the last 4 years, with Dec 2019 value amounting to $13.2 million.

  • Monopar Therapeutics' Cash & Equivalents rose 300.10% to $18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $18.0 million, marking a year-over-year increase of 300.10%. This contributed to the annual value of $13.2 million for FY2019, which is 91.71% up from last year.
  • As of FY2019, Monopar Therapeutics' Cash & Equivalents stood at $13.2 million, which was up 91.71% from $6.9 million recorded in FY2018.
  • Over the past 5 years, Monopar Therapeutics' Cash & Equivalents peaked at $13.2 million during FY2019, and registered a low of $2.9 million during FY2016.
  • Its 3-year average for Cash & Equivalents is $10.0 million, with a median of $9.8 million in 2017.
  • As far as peak fluctuations go, Monopar Therapeutics' Cash & Equivalents skyrocketed by 240.48% in 2017, and later fell by 29.54% in 2018.
  • Over the past 4 years, Monopar Therapeutics' Cash & Equivalents (Yearly) stood at $2.9 million in 2016, then surged by 240.48% to $9.8 million in 2017, then declined by 29.54% to $6.9 million in 2018, then skyrocketed by 91.71% to $13.2 million in 2019.